AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide.
It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.
The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices.
It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments.
The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings.
It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services.
The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets.
The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
Country | United States |
IPO Date | Mar 17, 1980 |
Industry | Medical - Instruments & Supplies |
Sector | Healthcare |
Employees | 14,500 |
CEO | Liam J. Kelly |
Contact Details
Address: 550 East Swedesford Road Wayne, Pennsylvania United States | |
Website | https://www.teleflex.com |
Stock Details
Ticker Symbol | TFX |
Exchange | NYSE |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000096943 |
CUSIP Number | 879369106 |
ISIN Number | US8793691069 |
Employer ID | 23-1147939 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Liam J. Kelly | Chairman, President & Chief Executive Officer |
Thomas E. Powell BS, MBA | Executive Vice President & Chief Financial Officer |
Timothy F. Duffy | Vice President & Chief Information Officer |
Cameron P. Hicks | Corporate Vice President & Chief Human Resources Officer |
Daniel V. Logue J.D. | Corporate Vice President, General Counsel & Secretary |
Howard Cyr | Corporate Vice President & Chief Compliance Officer |
James Ferguson | President & GM of Surgical |
Jay White | Corporate Vice President & President of Global Commercial |
John R. Deren | Corporate Vice President & Chief Accounting Officer |
Michelle Fox | Corporate Vice President & Chief Medical Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 08, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 07, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Oct 31, 2024 | 10-Q | Quarterly Report |
Oct 31, 2024 | 8-K | Current Report |
Aug 29, 2024 | 8-K | Current Report |
Aug 27, 2024 | 4 | Filing |
Aug 16, 2024 | 4 | Filing |
Aug 05, 2024 | 8-K | Current Report |